- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05010772
Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission
Oral Decitabine-Based Maintenance Therapy in Patients With AML in Remission
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To assess safety of patients with acute myeloid leukemia (AML) treated with decitabine and cedazuridine (oral decitabine)-based combinations as maintenance therapy after achieving remission.
SECONDARY OBJECTIVES:
I. To assess relapse-frees survival (RFS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy.
II. To assess overall survival (OS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy.
III. To assess event-free survival (EFS) of patients with AML treated with oral decitabine-based combinations as maintenance therapy.
IV. To assess the duration of remission (CRd) of patients with AML treated oral decitabine-based combinations as maintenance therapy.
V. To assess the effects of oral decitabine-based combinations on dynamics of minimal residual disease and their relationship to outcomes.
EXPLORATORY OBJECTIVE:
I. To evaluate RFS in (1) intensive induction cohort and (2) lower intensity induction cohort.
OUTLINE: Patients are assigned to 1 of 5 arms.
ARM A: Patients receive decitabine and cedazuridine orally (PO) once daily (QD) on days 1-3. Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
ARM B: Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
ARM C: Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
ARM D: Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
ARM E: Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28. Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6-12 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Tapan M. Kadia, MD
- Phone Number: 713-792-7305
- Email: tkadia@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Tapan M. Kadia
- Phone Number: 713-792-7305
- Email: tkadia@mdanderson.org
-
Principal Investigator:
- Tapan M. Kadia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients aged >= 18 years AML who have achieved their FIRST complete response (CR) or complete response with incomplete bone marrow recovery (CRi) and are not immediately candidates for allogeneic stem cell transplant
- Patients who have received intensive therapy (defined as receiving standard or higher dose cytarabine-based therapy) to achieve remission (CR/CRi) should have received remission induction therapy and at least 1 consolidation cycle. These patients are eligible as long as they are not greater than 2 months from their last consolidation therapy and will be designated as COHORT 1 (intensive induction cohort)
- Patients who have received lower intensity therapy (defined as receiving low-dose cytarabine [LDAC] or hypomethylating agent [HMA]-based therapy) to achieve remission should have received at least 2 cycles of lower intensity therapy between the time they have achieved CR/CRi and enrollment on this protocol. They will be designated as COHORT 2 (lower intensity induction cohort)
- For either subgroup (lower or higher intensity), patients who have measurable residual disease may be enrolled on their respective cohort at any time without maximum 'time from consolidation' requirement
- Eastern Cooperative Oncology Group (ECOG) performance status of < or = 3
- Serum total bilirubin < or = to 1.5 x the upper limit of normal (ULN)
- Serum creatinine < or = to 2.5 x ULN
- Absolute neutrophil count (ANC) > 0.5 x k/uL
- Platelet count > or = 50 x k/uL
For females of childbearing age, they may participate if they:
- Have a negative serum or urine pregnancy test within 10 to 14 days of enrolling
- Agree to either abstinence or 2 effective contraceptive methods (such as barrier methods or hormonal contraception) throughout the treatment period and up to 30 days after discontinuing treatment
- For male patients with a female partner of childbearing age, they may participate if they agree to either abstinence or 2 effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment
- Ability to understand and sign informed consent
Exclusion Criteria:
- Diagnosis of acute promyelocytic leukemia (APL), AML - M3 by French-American-British (FAB) classification based on morphology, immunophenotype, molecular, or cytogenetics studies
- Diagnosis of AML associated t(15;17) or APL variant. Patients with t(9;22) are also ineligible unless they are unable or unwilling to receive therapy with a tyrosine kinase inhibitor
- Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patients with active CNS (central nervous system) disease
- Patients with documented hypersensitivity to any components of the study program
- Females who are pregnant or lactating or intending to become pregnant during the study
- Patients with history of extramedullary AML, except for CNS involvement that is currently controlled, will not be eligible for enrollment
- Patient should be removed from current trial if they wish to participate and get treatment on another trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (decitabine and cedazuridine)
Patients receive decitabine and cedazuridine PO QD on days 1-3.
Treatments repeat every 28 days for up to 4 weeks in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
Experimental: Arm B (decitabine and cedazuridine, venetoclax)
Patients receive decitabine and cedazuridine PO QD on days 1-3 and venetoclax PO QD on days 1-5.
Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Given PO
Other Names:
|
Experimental: Arm C (decitabine and cedazuridine, gilteritinib)
Patients receive decitabine and cedazuridine PO QD on days 1-3 and gilteritinib PO QD on days 1-28.
Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Given PO
Other Names:
|
Experimental: Arm D (decitabine and cedazuridine, enasidenib)
Patients receive decitabine and cedazuridine PO QD on days 1-3 and enasidenib PO QD on days 1-28.
Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Given PO
Other Names:
|
Experimental: Arm E (decitabine and cedazuridine, ivosidenib)
Patients receive decitabine and cedazuridine PO QD on days 1-3 and ivosidenib PO QD on days 1-28.
Treatments repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events
Time Frame: Up to 5 years
|
Safety analyses in general will be descriptive and will be presented in tabular format with the appropriate summary statistics.
Adverse events will be tabulated using frequency and percentage by severity and by relations to the treatments for each arm.
|
Up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relapse-free survival (RFS)
Time Frame: From complete remission or complete remission with incomplete count recovery until date of first objective documentation of relapse or death, assessed up to 5 years
|
The Kaplan-Meier method will be used to estimate RFS.
|
From complete remission or complete remission with incomplete count recovery until date of first objective documentation of relapse or death, assessed up to 5 years
|
Overall survival (OS)
Time Frame: From date of treatment start until date of death due to any cause, assessed up to 5 years
|
The Kaplan-Meier method will be used to estimate OS.
|
From date of treatment start until date of death due to any cause, assessed up to 5 years
|
Event-free survival (EFS)
Time Frame: From treatment start until date of first documented event., assessed up to 5 years
|
Event will be defined as: confirmed relapse, withdrawal from study due to adverse event, or death due to any cause.
The Kaplan-Meier method will be used to estimate EFS.
|
From treatment start until date of first documented event., assessed up to 5 years
|
Duration of remission
Time Frame: Up to 5 years
|
The Kaplan-Meier method will be used to duration of remission.
|
Up to 5 years
|
Minimal residual disease
Time Frame: Up to 5 years
|
The log rank test and Cox proportional hazards model will be used to evaluate the association between the time to event outcomes and status of residual disease.
|
Up to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
RFS (Intensive induction cohort)
Time Frame: Up to 5 years
|
Kaplan-Meier method will be used to estimate RFS for intensive induction cohort.
|
Up to 5 years
|
RFS (Lower intensity induction cohort)
Time Frame: Up to 5 years
|
Kaplan-Meier method will be used to estimate RFS for lower intensity induction cohort.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tapan M Kadia, MD, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Hematologic Diseases
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Decitabine
- Venetoclax
- Ivosidenib
- Decitabine and cedazuridine drug combination
- Gilteritinib
Other Study ID Numbers
- 2021-0237 (Other Identifier: M D Anderson Cancer Center)
- NCI-2021-08496 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
Advesya SASNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryFrance, Sweden, Spain, Germany
-
Keystone Nano, IncMilton S. Hershey Medical Center; University of VirginiaNot yet recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, RefractoryUnited States
-
National Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Adult Acute Monoblastic Leukemia | Adult Acute Monocytic Leukemia | Adult Acute Myeloid Leukemia With Maturation | Adult Acute Myeloid Leukemia Without Maturation | Adult Acute Myelomonocytic Leukemia | Alkylating Agent-Related Acute Myeloid... and other conditionsUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Oryzon Genomics S.A.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
University Hospital, AntwerpRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryBelgium
-
Medical College of WisconsinRecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Stanford UniversityCelgene CorporationCompletedAcute Myeloid Leukemia (AML) | Adult Acute Myeloblastic LeukemiaUnited States
Clinical Trials on Venetoclax
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
BioSight Ltd.Recruiting
-
Aptose Biosciences Inc.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States, Germany, Spain, Korea, Republic of, Australia, New Zealand
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingChronic Lymphocytic LeukemiaUnited States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting